<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01307098</url>
  </required_header>
  <id_info>
    <org_study_id>LAL-CL01</org_study_id>
    <nct_id>NCT01307098</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Patients With Lysosomal Acid Lipase Deficiency</brief_title>
  <official_title>An Open Label Multicenter Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Patients With Liver Dysfunction Due to Lysosomal Acid Lipase Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first clinical study of SBC-102 (sebelipase alfa) for the treatment of LAL
      Deficiency. It is an open label dose escalation study in adult patients with liver
      dysfunction due to Lysosomal Acid Lipase (LAL) Deficiency and will examine three doses of
      SBC-102 (sebelipase alfa). The targeted number for this study is 9 evaluable subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cholesteryl Ester Storage Disease (CESD) is the late onset phenotype for Lysosomal Acid
      Lipase (LAL) Deficiency, a Lysosomal Storage Disorder, which also has an early onset
      phenotype known as Wolman Disease that primarily affects infants. CESD can present in
      childhood but often goes unrecognized until adulthood when the underlying pathology is
      advanced. Many of the signs and symptoms are common to patients with other liver conditions.

      CESD is an autosomal recessive genetic condition and is characterized by hepatomegaly,
      persistently abnormal liver function tests (LFTs) and type II hyperlipidemia. Splenomegaly
      and evidence of mild hypersplenism may affect some patients. Untreated, CESD may lead to
      fibrosis, cirrhosis, liver failure and death.

      Disease Risk In Families:

        -  25 per million incidence

        -  Autosomal recessive disorder, LAL deficiency is carried on chromosome 10

        -  Parents with an affected son or daughter have a 1 in 4 chance of having another affected
           child
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of SBC-102 (sebelipase alfa)</measure>
    <time_frame>4 weeks</time_frame>
    <description>The safety and tolerability of weekly infusions of SBC-102 (sebelipase alfa) will be assessed by routine monitoring of patients for adverse events (AEs) and monitoring changes from baseline in physical examination findings, vital signs, clinical laboratory evaluations, immunogenicity tests and concomitant therapies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SBC-102 (sebelipase alfa)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Characterize the pharmacokinetics of SBC-102 (sebelipase alfa) delivered by IV infusion after single and multiple doses.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Cholesterol Ester Storage Disease(CESD)</condition>
  <condition>Lysosomal Acid Lipase Deficiency</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: Weekly IV infusions of Dose A of SBC-102 (sebelipase alfa)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2: Weekly IV infusions of Dose B of SBC-102 (sebelipase alfa)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3: Weekly IV infusions of Dose C of SBC-102 (sebelipase alfa)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SBC-102 (sebelipase alfa)</intervention_name>
    <description>Weekly IV infusions Dose A of SBC-102 (sebelipase alfa)</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>Kanuma</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SBC-102 (sebelipase alfa)</intervention_name>
    <description>Weekly IV infusions Dose B of SBC-102 (sebelipase alfa)</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>Kanuma</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SBC-102 (sebelipase alfa)</intervention_name>
    <description>Weekly IV infusions Dose C of SBC-102 (sebelipase alfa)</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>Kanuma</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients ≥ 18 and ≤ 65 years of age

          -  Documented decreased LAL activity

          -  Evidence of liver involvement

        Exclusion Criteria:

          -  Clinically significant concurrent disease, serious inter-current illness, concomitant
             medications or other extenuating circumstances

          -  Clinically significant abnormal values on laboratory screening tests, other than liver
             function or lipid panel tests

          -  AST and/or ALT persistently elevated &gt; 3xULN at screening

          -  Previous hemopoietic bone marrow or liver transplant

          -  Current history of alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburg</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15524</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General University Hospital in Prague</name>
      <address>
        <city>Prague</city>
        <zip>12808</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Necker Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital, NHS Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB20QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M139WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://alexion.com</url>
    <description>Website</description>
  </link>
  <results_reference>
    <citation>Balwani M, Breen C, Enns GM, Deegan PB, Honzík T, Jones S, Kane JP, Malinova V, Sharma R, Stock EO, Valayannopoulos V, Wraith JE, Burg J, Eckert S, Schneider E, Quinn AG. Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients with cholesteryl ester storage disease. Hepatology. 2013 Sep;58(3):950-7. doi: 10.1002/hep.26289. Epub 2013 Mar 28.</citation>
    <PMID>23348766</PMID>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2011</study_first_submitted>
  <study_first_submitted_qc>March 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2011</study_first_posted>
  <last_update_submitted>July 26, 2016</last_update_submitted>
  <last_update_submitted_qc>July 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Enzyme Replacement Therapy (ERT)</keyword>
  <keyword>Lysosomal Storage Disease</keyword>
  <keyword>Late Onset Lysosomal Acid Lipase (LAL) Deficiency</keyword>
  <keyword>Acid cholesteryl ester hydrolase deficiency, type 2</keyword>
  <keyword>Acid lipase disease</keyword>
  <keyword>Cholesterol ester hydrolase deficiency</keyword>
  <keyword>LAL Deficiency</keyword>
  <keyword>LIPA Deficiency</keyword>
  <keyword>Wolman disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wolman Disease</mesh_term>
    <mesh_term>Cholesterol Ester Storage Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

